How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
4
NONOF Quote, Financials, Valuation and Earnings
Last price:
$47.22
Seasonality move
:
7.77%
Day range:
$45.15 - $49.12
52-week range:
$42.01 - $93.83
Dividend yield:
3.66%
P/E ratio:
13.62x
P/S ratio:
4.50x
P/B ratio:
7.85x
Volume:
583.6K
Avg. volume:
158.7K
1-year change:
-43.52%
Market cap:
$209.8B
Revenue:
$46.7B
EPS (TTM):
$3.47
Analysts' Opinion
-
Consensus RatingNovo Nordisk A/S has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $53.99, Novo Nordisk A/S has an estimated upside of 14.31% from its current price of $47.22.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $53.99 representing 100% downside risk from its current price of $47.22.
Fair Value
-
According to the consensus of 1 analyst, Novo Nordisk A/S has 14.31% upside to fair value with a price target of $53.99 per share.
NONOF vs. S&P 500
-
Over the past 5 trading days, Novo Nordisk A/S has underperformed the S&P 500 by -19.06% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Novo Nordisk A/S does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Novo Nordisk A/S has grown year-over-year revenues for 22 quarters straight. In the most recent quarter Novo Nordisk A/S reported revenues of $12.3B.
Earnings Growth
-
Novo Nordisk A/S has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Novo Nordisk A/S reported earnings per share of $0.94.
Enterprise value:
226.2B
EV / Invested capital:
4.43x
Price / LTM sales:
4.50x
EV / EBIT:
11.75x
EV / Revenue:
4.84x
PEG ratio (5yr expected):
2.42x
EV / Free cash flow:
50.06x
Price / Operating cash flow:
46.55x
Enterprise value / EBITDA:
10.00x
Gross Profit (TTM):
$37.8B
Return On Assets:
20.47%
Net Income Margin (TTM):
33.03%
Return On Equity:
62.44%
Return On Invested Capital:
37.26%
Operating Margin:
40.32%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $33.7B | $42.1B | $46.8B | $12.3B | $12.3B | |
| Gross Profit | $28.5B | $35.6B | $37.8B | $10.4B | $10B | |
| Operating Income | $14.9B | $18.9B | $19.3B | $5.5B | $5B | |
| EBITDA | $16.2B | $21.7B | $22.6B | $6.3B | $5.8B | |
| Diluted EPS | $2.70 | $3.28 | $3.47 | $0.91 | $0.94 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $13.1B | $15.5B | $20.7B | $22.3B | $27.1B | |
| Total Assets | $29.7B | $34.6B | $46.6B | $64.7B | $85.4B | |
| Current Liabilities | $15.2B | $17.4B | $25.1B | $30.2B | $33.9B | |
| Total Liabilities | $18.9B | $22.6B | $30.8B | $44.8B | $54.9B | |
| Total Equity | $10.8B | $12B | $15.8B | $19.9B | $30.5B | |
| Total Debt | $2B | $3.6B | $3.2B | $12.6B | $18.7B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $15.8B | $17.1B | $18.6B | $1.3B | $1.1B | |
| Cash From Investing | -$6.4B | -$18.4B | -$12.3B | -$12.9B | -$6.6B | |
| Cash From Financing | -$9.2B | $1.2B | -$4.4B | $5.4B | $4.6B | |
| Free Cash Flow | $10.2B | $9.8B | $4.5B | -$921.8M | -$5.7B | |
NONOF
Sector
Market Cap
$209.8B
$23.7M
Price % of 52-Week High
50.33%
49.4%
Dividend Yield
3.66%
0%
Shareholder Yield
2.42%
-1.67%
1-Year Price Total Return
-43.52%
-20.73%
Beta (5-Year)
0.650
0.502
Dividend yield:
3.66%
Annualized payout:
$1.73
Payout ratio:
--
Growth streak:
6 years
Technicals
8-day SMA
Sell
Level
$57.78
200-day SMA
Sell
Level
$58.57
Bollinger Bands (100)
Sell
Level
48.37 - 58.81
Chaikin Money Flow
Sell
Level
-1.1M
20-day SMA
Sell
Level
$58.67
Relative Strength Index (RSI14)
Sell
Level
34.07
ADX Line
Sell
Level
26.19
Williams %R
Buy
Level
-89.4388
50-day SMA
Sell
Level
$53.08
MACD (12, 26)
Buy
Level
13.17
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Sell
Level
-1.7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.1847)
Buy
CA Score
(Annual)
Level (0.1896)
Buy
Beneish M-Score
(Annual)
Level (-2.5103)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-1.3757)
Buy
Piotroski F Score
(Annual)
Level (5)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Stock Forecast FAQ
In the current month, NONOF has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The NONOF average analyst price target in the past 3 months is $53.99.
-
Where Will Novo Nordisk A/S Stock Be In 1 Year?
According to analysts, the consensus estimate is that Novo Nordisk A/S share price will rise to $53.99 per share over the next 12 months.
-
What Do Analysts Say About Novo Nordisk A/S?
Analysts are divided on their view about Novo Nordisk A/S share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Novo Nordisk A/S is a Sell and believe this share price will drop from its current level to $53.99.
-
What Is Novo Nordisk A/S's Price Target?
The price target for Novo Nordisk A/S over the next 1-year time period is forecast to be $53.99 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is NONOF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Novo Nordisk A/S is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of NONOF?
You can purchase shares of Novo Nordisk A/S via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Novo Nordisk A/S shares.
-
What Is The Novo Nordisk A/S Share Price Today?
Novo Nordisk A/S was last trading at $47.22 per share. This represents the most recent stock quote for Novo Nordisk A/S. Yesterday, Novo Nordisk A/S closed at $47.22 per share.
-
How To Buy Novo Nordisk A/S Stock Online?
In order to purchase Novo Nordisk A/S stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get NONOF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NONOF
Sector
P/E ratio
13.62x
23.26x
PEG ratio
2.42x
-0.01x
P/B ratio
7.85x
1.77x
Price / LTM sales
4.50x
1.54x
Growth Metrics
NONOF
Sector
Revenue growth
0.66%
3.94%
Earnings growth
3.89%
9.72%
Revenue (5-year growth)
19.21%
6.15%
Earnings forecast
--
-$0.19
Profitability
NONOF
Sector
Profitability FY 2025
$37.8B
$2.7M
Return on invested capital
37.26%
-33.43%
Return on assets
20.47%
-29.68%
Return on equity
62.44%
-38.98%
Earnings Date
Last Earnings Date
Feb
3
Next Earnings Date
May
6
Estimated Next Earnings Date
May
5
Balance Sheet
NONOF
Sector
Total cash
$4.2B
$25M
Short term investments
$1.5B
$23.9M
Total assets
$85.4B
$71.9M
Long term debt
$18.7B
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
73
ENPH alert for Feb 5
Enphase Energy, Inc. [ENPH] is up 38.57% over the past day.
Sell
1
PYPL alert for Feb 5
PayPal Holdings, Inc. [PYPL] is down 1.61% over the past day.
Sell
46
SHNY alert for Feb 5
MicroSectors Gold 3X Leveraged ETN [SHNY] is up 0.3% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
